Months sooner than expected, Zogenix Inc. said it's planning to resubmit an NDA for Fintepla (ZX-008, fenfluramine hydrochloride), a drug for seizures associated with Dravet syndrome (DS) that received a refusal to file (RTF) letter from the FDA in April.